ClinicalTrials.gg
RecruitingNCT07258745Updated Dec 19, 2025

Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants

A Phase 1 interventional study of SKYRIZI and SKYRIZI in Psoriasis, sponsored by Chong Kun Dang Pharmaceutical. Recruiting at 1 site in Poland. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-19.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
213
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 166 studies in Psoriasis with a site in Poland — 7 open to participants now, 20 under way, 18 of them phase 3. Psoriasis · Poland.

Planned enrollment
112th of 162
213 · median 376
Started
2025
with 11 others
Phase 1
4 of 166
1 open now
Primary completion
2026-09
later than 9 of 19 live
Registered
165th of 166
by date

Among the 166 studies in Psoriasis with a site in Poland, this one is the 112th largest by planned enrollment of the 162 interventional ones that give a count, is one of 12 that started in 2025, is one of 4 in phase 1, reaches primary completion later than 9 of the 19 other live ones, and was the 165th registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

7 of the 166 studies in Psoriasis with a site in Poland are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 174 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 166 studies in Psoriasis with a site in Poland, or all of them as a file.
02

Study summary

This is a Phase 1, first-in-human (FIH), randomized, double-blind, single-dose, parallel-group, 3-arm study to compare PK, safety, tolerability, and immunogenicity profiles of CKD-704, EU-approved Skyrizi, and US-licensed Skyrizi in healthy adult participants.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • Psoriasis
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capability of giving signed and complying with the requirements and restrictions listed in the ICF and Protocol
  • Healthy male or female, 18 to 55 years (inclusive) at the time of signing the ICF
  • smokes ≤ 10 cigarettes per week within 3 months of screening
  • abstain from alcohol from 48 hours prior to study intervention administration and keeping alcohol consumption within WHO limits (more than 14 units per week spread over 3 or more days, equivalent to 6 pints of average strength beer or 6 medium glasses [175 mL] of wine)
  • have acceptable venous access for blood collection
  • Female participants are eligible to participate if they are not pregnant, not breastfeeding
  • Male participants must refrain from donating sperm from screening (signing the ICF) until at least 30 days after EOS visit
  • All participants must be willing to use effective/highly effective methods of during the study period
  • Participants are willing and able to be confined to the clinical unit prior to and during the study intervention administration and required follow-up periods.

Exclusion criteria

Exclusion Criteria:

  • History of previous exposure to any anti-IL-12/23 or anti-IL-23 treatment
  • History of relevant drug and/or food allergies
  • History of to Skyrizi or their constituents
  • Presence of psychiatric disorders or altered mental status precluding understanding of the process and/or completion of the necessary procedures
  • Medical history, findings of physical examination/laboratory tests indicate a disorder, condition, or disease that, in the opinion of the Investigator would pose a risk to participant safety
  • Major surgery within 12 weeks prior to the randomization into the study
  • Documented active or suspected or history of malignancy within 5 years prior to screening
  • Positive tests for surface antigen, Hepatitis B core antibody, virus antibody, or (HIV)-1 and HIV-2 antibody at screening
  • Positive test for severe acute respiratory syndrome coronavirus 2 on admission (optional)
  • Any current active infections or any recent history (within 1 week prior to study intervention administration) of active infections
  • Participant has a history of tuberculosis (TB) diagnosis or evidence of active or latent infection with Mycobacterium tuberculosis
  • Abnormal hepatic, renal, or hematological laboratory tests. In such cases, the assessment may be repeated once at screening and admission. The Investigator will check reassessment results to decide if the value is clinically significant and if participant is eligible to receive the treatment
  • Any other laboratory value outside the reference range that the Investigator considers to be of clinical significance
  • Abnormal vital signs(Systolic blood pressure \< 90 mmHg or > 140 mmHg, Diastolic blood pressure \< 50 mmHg or > 90 mmHg, Heart rate \< 45 or > 100 beats per minute)
  • Any clinically important abnormalities in rhythm, conduction, or morphology of the resting and any clinically important abnormalities in the 12-lead ECG
  • Any past or concurrent medical conditions, or clinically important active infection that could potentially increase the participant's risks or that would interfere with the study evaluation, procedures, or study completion
  • Have used any prescription or non-prescription medicines or vitamins within 7 days or 5 half-lives (whichever is longer) of admission, unless in the Investigator's opinion will not affect determination of safety or other study assessments
  • Male or females participating in any other clinical trial at the time of consenting
  • Have received any drug within 30 days prior to screening, with minimal of at least 5-half-lives of any previous investigational drug, whichever is longer
  • Have received during the past 4 weeks before screening or have the intention to receive vaccination during the 21-week treatment and assessment period
  • Participant has donated blood (> 500 mL) or blood products within 2 months (56 days) prior to screening
  • History of drug abuse or alcohol abuse as judged by the Investigator or designee
  • Participant is affiliated with the site or Sponsor and/or may be considered to be consenting under duress
  • Participant is unlikely to co-operate with the requirements of the study
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
213 participants (estimated)

Study arms

  • Experimental
    CKD-704

    Singe dose pre-filled syringe, 150mg/ml

    Biological: CKD-704

  • Active comparator
    EU-Skyrizi

    Singe dose pre-filled syringe, 150mg/ml

    Biological: SKYRIZI

  • Active comparator
    US-Skyrizi

    Singe dose pre-filled syringe, 150mg/ml

    Biological: SKYRIZI

Interventions

  • BiologicalSKYRIZI

    EU-sourced

  • BiologicalSKYRIZI

    US-licensed

  • BiologicalCKD-704

    Risankizumab biosimilar

06

What researchers measure

Primary outcomes

  1. Maximum Observed Serum Concentration (Cmax)

    Maximum observed serum concentration (Cmax) of risankizumab.

    Time frame: up to approximately 146 days

  2. AUC From Time 0 to Infinity (AUCinf)

    AUCinf of risankizumab

    Time frame: Up to approximately 146 days

Secondary outcomes

  1. Area Under Concentration-Time Curve (AUC) From Time 0 to Time of the Last Measurable Concentration (AUCt)

    AUCt of risankizumab

    Time frame: Up to approximately 146 days

  2. Terminal Phase Elimination Hhalf-life (t1/2)

    Terminal phase elimination half-life (t1/2) of risankizumab.

    Time frame: Up to approximately 146 days

  3. Time to Cmax (Tmax)

    Time to Cmax of risankizumab

    Time frame: Up to approximately 146 days

  4. Safety and tolerability

    Incidence and characteristics (severity, etc) of AEs

    Time frame: Up to approximately 146 days

07

Study locations

1 of 1 sites recruiting
  • MTZ powered by Pratia
    Warsaw, Warszawa 02-172, Poland
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Sep 2026, 10 months after the start.

Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 10 months is close to that.

Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Dec 2, 2025
StartActual
Nov 26, 2025
Primary completionEst.
Sep 30, 2026
CompletionEst.
Sep 30, 2026
Last update
Dec 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07258745
Responsible party
Sponsor
First posted
Dec 2, 2025
Start date
Nov 26, 2025
Primary completion
Sep 30, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Dec 19, 2025

Study contacts

Anna Dryja, MD
Contact
anna.dryja@pratia.com
+48 22 572 59 59

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion